- Capital Cube•29 days ago
Click here to see latest analysisGrifols SA reports financial results for the quarter ended March 31, 2016.We analyze the earnings along side the following peers of Grifols SA – Johnson & Johnson (JNJ-US) that have also reported for this period.HighlightsSummary numbers: Revenues of USD 1,057.43 million, Net Earnings of USD 138.11 million.Gross margins widened from […] (Read more...) The post Grifols SA :GRFS-US: Earnings Analysis: Q1, 2016 By the Numbers : July 26, 2016 appeared first on CapitalCube.
- Capital Cube•last month
Click here to see latest analysisETF’s with exposure to Grifols SAHere are 5 ETF’s with the largest exposure to GRFS-US. Comparing the performance and risk of Grifols SA with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility.TickerFund NameGRFS-US Exposure (%)1 Year Price […] (Read more...) The post ETF’s with exposure to Grifols SA : July 25, 2016 appeared first on CapitalCube.
- Capital Cube•last monthGrifols SA : GRFS-US: Dividend Analysis : June 06th, 2016 (record date) : By the numbers : July 12, 2016
Click here to see latest analysisOur analysis is based on comparing Grifols SA with the following peers – Baxter International Inc., China Biologic Products, Inc., Amgen Inc., China Cord Blood Corporation, Kimberly-Clark Corporation, Johnson & Johnson, Cord Blood America, Inc., Aradigm Corporation and Mylan N.V. (BAX-US, CBPO-US, AMGN-US, CO-US, KMB-US, JNJ-US, CBAI-US, ARDM-US and MYL-US).Grifols […] (Read more...) The post Grifols SA : GRFS-US: Dividend Analysis : June 06th, 2016 (record date) : By the numbers : July 12, 2016 appeared first on CapitalCube.
Grifols, S.A. (GRFS)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||12.43 x 100|
|Day's Range||16.23 - 16.67|
|52wk Range||14.07 - 18.04|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||37.13|
|Avg Vol (3m)||1,063,153|
|Dividend & Yield||0.52 (3.16%)|